Synta Pharmaceuticals, Inc.
GPTKB entity
Properties (67)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Company
|
| gptkbp:acquisition |
Merger_with_Madrigal_Pharmaceuticals
|
| gptkbp:businessModel |
Business development strategies
Biotech business model |
| gptkbp:CEO |
gptkb:Safi_Bahcall
|
| gptkbp:clinicalTrials |
Cancer treatment
Efficacy studies Clinical practice guidelines Clinical data management Phase 1 trials Phase 2 trials Clinical trial sites Clinical research studies Clinical outcome measures Design of clinical trials Phase 3 trials for elesclomol Results published in journals Targeting cancer metabolism Therapeutic development processes |
| gptkbp:collaborations |
Partnerships with academic institutions
|
| gptkbp:communityPartnerships |
Partnerships with pharmaceutical companies
Partnerships with healthcare providers |
| gptkbp:customerFeedback |
Patient feedback mechanisms
|
| gptkbp:drugInterdiction |
Drug approval process
Drug formulation techniques Innovative drug discovery methods |
| gptkbp:employees |
Approximately 50
|
| gptkbp:environmentalConcerns |
Biomarker_identification
|
| gptkbp:financialPerformance |
Patents_on_drug_compounds
|
| gptkbp:financials |
Annual financial reports
|
| gptkbp:focusesOn |
cancer therapeutics
|
| gptkbp:founded |
2007
|
| gptkbp:funding |
Venture capital funding
|
| gptkbp:hasPrograms |
Advisory board members
|
| gptkbp:hasResearchInterest |
Market analysis
|
| gptkbp:headquarters |
gptkb:Lexington,_Massachusetts
|
| gptkbp:healthcare |
Patient advocacy groups
Patient care initiatives Patient recruitment strategies Health outcome measures |
| gptkbp:historicalResearch |
Joint research initiatives
|
| https://www.w3.org/2000/01/rdf-schema#label |
Synta Pharmaceuticals, Inc.
|
| gptkbp:investmentFocus |
Institutional investors
Investor presentations |
| gptkbp:market |
Pharmaceutical market
U.S._market |
| gptkbp:marketSegment |
Market entry strategies
|
| gptkbp:notableEvent |
gptkb:elesclomol
|
| gptkbp:partnerships |
Collaboration with other biotech firms
|
| gptkbp:products |
Small molecule drugs
|
| gptkbp:regulatoryCompliance |
Compliance with regulations
FDA_approval_process |
| gptkbp:research_areas |
Hematology
Innovative therapies Solid tumors |
| gptkbp:researchAreas |
oncology
|
| gptkbp:researchFocus |
Mitochondrial function
|
| gptkbp:researchInterest |
Research publications
Research funding grants Collaboration with research hospitals |
| gptkbp:safetyFeatures |
Safety assessments
|
| gptkbp:stockSymbol |
SNTA
|
| gptkbp:subsidiary |
gptkb:Synta_Pharmaceuticals,_LLC
|
| gptkbp:tradedOn |
gptkb:NASDAQ
|
| gptkbp:tributaryOf |
Drug development pipeline
|
| gptkbp:updates |
Quarterly updates
|
| gptkbp:website |
www.syntapharma.com
|